Revance Therapeutics, Inc. (RVNC)
NASDAQ: RVNC · IEX Real-Time Price · USD
-0.290 (-6.82%)
At close: Jul 17, 2024, 4:00 PM
-0.010 (-0.25%)
After-hours: Jul 17, 2024, 7:32 PM EDT

Company Description

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.

The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids.

It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA.

The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005.

Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Revance Therapeutics, Inc.
Revance Therapeutics logo
Country United States
Founded 1999
IPO Date Feb 6, 2014
Industry Biotechnology
Sector Healthcare
Employees 597
CEO Mark J. Foley

Contact Details

1222 Demonbreun Street, Suite 2000
Nashville, Tennessee 37203
United States
Phone (615) 724-7755

Stock Details

Ticker Symbol RVNC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001479290
CUSIP Number 761330109
ISIN Number US7613301099
Employer ID 77-0551645
SIC Code 2834

Key Executives

Name Position
Mark J. Foley Chief Executive Officer and Director
Tobin C. Schilke Chief Financial Officer and Principal Accounting Officer
Dwight O. Moxie Chief Legal Officer and General Counsel
Jessica Serra Head of Investor Relations and ESG
Jeanie D. Herbert Senior Director of Investor Relations and Corporate Communications
Taryn Conway Vice President of Marketing
Amie Krause Chief People Officer
Dr. Conor Gallagher Head of Medical Affairs and Aesthetics
Dr. David A. Hollander M.B.A., M.D. Chief Medical Officer of Global Therapeutics Franchise Lead
Erica Jordan Chief Commercial Officer

Latest SEC Filings

Date Type Title
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
May 3, 2024 8-K Current Report
Apr 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 21, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 21, 2024 DEF 14A Other definitive proxy statements
Mar 18, 2024 144 Filing
Mar 18, 2024 144 Filing
Mar 18, 2024 144 Filing
Mar 5, 2024 8-K Current Report